A phase I trial of WP1066 was performed to evaluate its effects in the treatment of melanoma and glioblastoma (NCT01904123).320 Gandotinib (LY2784544) is an orally potent inhibitor of JAK1 and JAK2.274 Clinical studies have demonstrated that gandotinib has adequate efficacy, safety, and tolerability profiles in patients with myeloproliferative neoplasms (NCT01594723). The gene discussed is JAK2; the disease is myeloproliferative disorder.